menu
    • menu
    [{"orgOrder":0,"company":"Chugai Pharma Europe","sponsor":"Helsinn Advanced Synthesis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Helsinn, Chugai renew partnership to sell AKYNZEO\u00ae in UK and Ireland","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Agreement","leadProduct":"Fosnetupitant Chloride","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Chugai Pharma Europe","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chugai Pharma Europe \/ Chugai Pharma Europe","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pharma Europe \/ Chugai Pharma Europe"}]

    Find Clinical Drug Pipeline Developments & Deals by Chugai Pharma Europe

    Menu

    Chugai Pharma Europe

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Chugai Pharma Europe

                            United Kingdom arrow
                            Luxepack
                            Not Confirmed

                            Chugai Pharma Europe

                            United Kingdom arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fosnetupitant Chloride,Palonosetron,Dexamethasone

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Recipient : Helsinn Advanced Synthesis

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Helsinn, Chugai renew partnership to sell AKYNZEO® in UK and Ireland

                            Details : The agreement aims to commercialise Akynzeo (combination of netupitant-palonosetron), for the treatment of chemotherapy-induced nausea and vomiting (CINV) in adult patients, in UK and Ireland.

                            Brand Name : Akynzeo

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 12, 2024

                            Lead Product(s) : Fosnetupitant Chloride,Palonosetron,Dexamethasone

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Recipient : Helsinn Advanced Synthesis

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth